Clinical application of obinutuzumab for treating chronic lymphocytic leukemia

References

• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215. doi:10.1182/blood-2015-06-65112526486789
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174. doi:10.1016/S0140-6736(10)61381-520888994
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309. doi:10.1182/blood-2015-09-66767526492934
   PubMed Web of Science ®Google Scholar
• Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10(6):588–596.
   PubMed Web of Science ®Google Scholar
• Chaudhry M, Cheson BD. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows? Expert Rev Hematol. 2015;8(6):733–742. doi:10.1586/17474086.2015.108784426368831
   PubMed Web of Science ®Google Scholar
• Gagez AL, Cartron G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 2014;26(5):484–491. doi:10.1097/CCO.000000000000010725014645
   PubMed Web of Science ®Google Scholar
• Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin’s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015;38(4):185–192. doi:10.1159/00038152425877943
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–4402. doi:10.1182/blood-2009-06-22597920194898
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669–12674. doi:10.1073/pnas.110845510821768335
   PubMed Web of Science ®Google Scholar
• Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther. 2009;3:7–16.
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031–2042. doi:10.1158/1535-7163.MCT-12-118223873847
   PubMed Web of Science ®Google Scholar
• Kern DJ, James BR, Blackwell S, et al. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leu Lymphoma. 2013;54(11):2500–2505. doi:10.3109/10428194.2013.781169
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol. 2014;192(12):5618–5624. doi:10.4049/jimmunol.140028824795454
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 2014;192(5):2252–2260. doi:10.4049/jimmunol.130124924489098
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143–2159. doi:10.1172/JCI3788419620786
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–758. doi:10.1182/blood.v99.3.75411806974
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22–33. doi:10.4161/mabs.2277123211638
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530–2540. doi:10.1182/blood-2011-01-33035721768293
   PubMed Web of Science ®Google Scholar
• SA B, CH C, RR F, MS C, MJ G. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107–114. doi:10.1053/j.seminhematol.2010.01.00120350657
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124(14):2196–2202.25143487
   PubMed Web of Science ®Google Scholar
• Byrd JC, Flynn JM, Kipps TJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127(1):79–86. doi:10.1182/blood-2015-03-63439426472752
   PubMed Web of Science ®Google Scholar
• Brown JR, O’ Brien S, Kingsley CD, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015;125(18):2779–2785. doi:10.1182/blood-2014-12-61357025769620
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110. doi:10.1056/NEJMoa131398424401022
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–3491. doi:10.1182/blood-2013-05-50404324106207
   PubMed Web of Science ®Google Scholar
• Innocenti I, Autore F, Pasquale R, Morelli F, Efremov DG, Laurenti L. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2017;10(12):1069–1076. doi:10.1080/17474086.2017.139864229082795
   PubMed Web of Science ®Google Scholar
• Tam C, Kuss B, Opat S, Boulos J, Marlton P. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Intern Med J. 2017;5–10. doi:10.1111/imj.13493
   Web of Science ®Google Scholar
• Długosz-Danecka M, Jurczak W, Łątka-Cabała E, et al. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis. Pol Arch Internal Med. 2018;128:421–426.30057377
   PubMedGoogle Scholar
• Llambi F, Moldoveanu T, Tait SW, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44(4):517–531. doi:10.1016/j.molcel.2011.10.00122036586
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.304823291630
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016;27(5):778–787. doi:10.1093/annonc/mdw02926802148
   PubMed Web of Science ®Google Scholar
• Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139–142. doi:10.1111/bjh.1245723826785
   PubMed Web of Science ®Google Scholar
• Sampath D, Herter S, Ingalla E, et al. Abstract A245: combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies. Mol Cancer Ther. 2013;12(11 Supplement):A245–A245.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Gribben JG, Dyer MJS. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765–2775. doi:10.1182/blood-2019-01-89629030862645
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa181528131166681
   PubMed Web of Science ®Google Scholar
• Da Cunha-Bang C, Niemann CU. Targeting bruton’s tyrosine kinase across B-cell malignancies. Drugs. 2018;78(16):1653–1663. doi:10.1007/s40265-018-1003-630390220
   PubMed Web of Science ®Google Scholar
• Pal SS, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. doi:10.1186/s12943-018-0779-z29455639
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi:10.1016/S1470-2045(18)30788-530522969
   PubMed Web of Science ®Google Scholar
• Velez LJ, Lengerke-Diaz PA, Jacobs C, et al. Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2019;132(Suppl 1):1864. doi:10.1182/blood-2018-99-119523
   Web of Science ®Google Scholar
• von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019;33(5):1161–1172. doi:10.1038/s41375-018-0313-830568174
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591–594. doi:10.1182/blood-2010-03-27530520959606
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3ʹ-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603–3612. doi:10.1182/blood-2011-05-35249221803855
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117(16):4323–4327. doi:10.1182/blood-2010-11-31570521378270
   PubMed Web of Science ®Google Scholar
• Göckeritz E, Kerwien S, Baumann M, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015;137(9):2234–2242. doi:10.1002/ijc.2957925912635
   PubMed Web of Science ®Google Scholar
• Miller BW, Przepiorka D, de Claro RA, et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res. 2015;21(7):1525–1529. doi:10.1158/1078-0432.CCR-14-252225645861
   PubMed Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110(7):2569–2577. doi:10.1182/blood-2006-12-06292717440052
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Schmied L, Stern M. How to outsmart NK cell tolerance. Oncoimmunology. 2015;4(9):e1016708. doi:10.1080/2162402X.2015.100837126405590
   PubMed Web of Science ®Google Scholar
• Buechele C, Baessler T, Schmiedel BJ, et al. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol. 2012;42(3):737–748. doi:10.1002/eji.20114192022144129
   PubMed Web of Science ®Google Scholar